Huakang Biomedical Holdings Company Limited (HKG:8622)
Hong Kong · Delayed Price · Currency is HKD 0.3600
+0.0200 (5.88%)
Jul 18, 2025, 3:08 PM HKT
HKG:8622 Revenue
In the year 2024, Huakang Biomedical Holdings Company had annual revenue of 25.36M CNY with 2.96% growth. Huakang Biomedical Holdings Company had revenue of 6.72M in the quarter ending December 31, 2024, a decrease of -1.96%.
Revenue
25.36M CNY
Revenue Growth
+2.96%
P/S Ratio
6.31
Revenue / Employee
278.67K CNY
Employees
91
Market Cap
170.16M HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 25.36M | 730.00K | 2.96% |
| Dec 31, 2023 | 24.63M | -701.00K | -2.77% |
| Dec 31, 2022 | 25.33M | -797.00K | -3.05% |
| Dec 31, 2021 | 26.13M | 4.16M | 18.94% |
| Dec 31, 2020 | 21.97M | -3.50M | -13.76% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BeOne Medicines | 32.49B |
| Hansoh Pharmaceutical Group Company | 13.05B |
| Innovent Biologics | 10.03B |
| JD Health International | 61.89B |
| Sino Biopharmaceutical | 30.72B |
| WuXi Biologics | 19.87B |
| Akeso | 2.26B |
| CSPC Pharmaceutical Group | 28.99B |